Skip to main content
EHCEncompass Health CorporationBuy Wait5.8·$122.09
Buy WaitModerate Confidence
Investment thesis

Encompass Health has delivered four consecutive earnings beats and offers 23 percent upside to the analyst target with a strongly favorable risk/reward geometry, but a confirmed price downtrend and elevated put/call activity signal the market has not yet recognized the opportunity — patience is warranted until the technical picture stabilizes.

Thesis pillars

  • Perfect Four Quarter Beat Streak↑Improving
  • Compelling Upside Favorable Risk Reward→Stable
  • Confirmed Downtrend Entry Risk↑Improving
  • +1 more pillar — see the Why tab for full reasoning

Pillars as of Jul 3, 2026, based on the 10-K filed Feb 26, 2026

Full reasoning →

Open full analysis

Encompass Health Corporation (EHC) Stock Analysis

Range Bound setup

Buy WaitVALUE-TRAP 1/5QualityModerate Confidence

Healthcare · Medical Care Facilities

Wait for pullback to $120.07. At $122.09 the A.R:R is 1.0:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $120.07 (support + ATR (held)) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risk: Thin upside margin: 5.6%.

Encompass Health Corporation is the nation's largest owner and operator of inpatient rehabilitation hospitals, operating 173 facilities across 39 states and Puerto Rico, with concentrations in Florida and Texas. The company generated $5.9 billion in net operating revenues in... Read more

$122.09+5.6% A.UpsideScore 5.8/10#12 of 35 Medical Care Facilities
QualityF-score7 / 9FCF yield1.91%
IncomeYield0.69%(5y avg 0.85%)Payout12.71%sustainable
Entry $120.07(support + ATR (held))Stop $114.84Target $128.91(analyst − 13%)A.R:R 1.0:1
Analyst consensus$148.17+21.4%12 analysts
$128.91our TP
$122.09price
$148.17mean
$155

Wait for pullback to $120.07. At $122.09 the A.R:R is 1.0:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $120.07 (support + ATR (held)) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risk: Thin upside margin: 5.6%. Chart setup: RSI 49 mid-range, Bollinger mid-band. Maintain position. Not compelling to add more. | News modifier +2 (HOLD_IF_HOLDING → STRONG_BUY_WAIT) Score 5.8/10, moderate confidence.

Passes 7/9 gates (positive momentum, clean insider activity, no SEC red flags, news boost earnings 0.80, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.

10-K grounded · weekly refresh

About Encompass Health Corporation

About Encompass Health Corporation

Encompass Health Corporation operated 173 inpatient rehabilitation hospitals across 39 states and Puerto Rico at December 31, 2025, generating total net operating revenues of $5.9 billion — up from $5.4 billion in 2024 — and treating 263,299 patients through discharge. Concentrations in Florida and Texas reflect the company's strategy of expanding in high-growth demographic markets. The company has opened or acquired 78 new hospitals and increased licensed bed count by approximately 72% since 2012, and employed over 42,000 individuals at year-end.

Encompass Health earns revenue primarily through Medicare reimbursement under the inpatient rehabilitation facility prospective payment system, alongside Medicare Advantage, Medicaid, and commercial payors. Substantially all (92%) of patients are admitted from acute-care hospitals following physician referrals — a structure that makes the company dependent on relationships with referring hospitals and health systems. More than a third of hospitals operate as joint ventures with acute-care systems, creating referral alignment. The company competes against rehabilitation units within acute-care hospitals, privately held post-acute care providers, and one publicly traded company operating 38 inpatient rehabilitation hospitals. The target patient demographic is concentrated in Medicare beneficiaries aged 65 and older, where the population of age 75 and over is expected to grow at approximately 4% per year through 2030, providing long-term demand growth.

Show full overview

Medicare reimbursement risk is the dominant regulatory exposure. The 10-K identifies restrictive coverage determinations by Medicare Advantage plans during pre-authorization as a material threat to revenues, while also noting that changes in payment system re-basing or the introduction of value-based models could reduce revenues if not offset by demonstrated outcome superiority. The company has pursued improvement in MA payments by demonstrating higher discharge-to-community rates and lower lengths of stay versus alternative care sites. If CMS re-bases the IRF payment system or reduces rates, Encompass Health's revenues and operating margins could be materially affected.

See also: Healthcare · Medical Care Facilities

From Encompass Health Corporation's most recent 10-K filing, extracted June 10, 2026.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated 2026-10-29
TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Wed, Oct 28, 2026Date unconfirmed· next earnings call

Thesis

Rewards
Sector modifier (Healthcare): +0.5
Strong earnings beat streak (4/4)
Positive news sentiment (+0.78)
Risks
Thin upside margin: 5.6%

Key Metrics

P/E (TTM)20.4
P/E (Fwd)18.3
Mkt Cap$12.0B
EV/EBITDA10.7
Profit Mgn10.0%
ROE25.0%
Rev Growth9.6%
Beta0.60
Dividend0.69%
Rating analysts18

Quality Signals

Piotroski F7/9MoatNarrow

Options Flow

P/C19.25bearish
IV46%normal
Max Pain$155+27.0% vs spot

Concentration Risks(10-K Item 1A)

  • MEDIUMGeographicFlorida and Texas
    10-K Item 1: 'We operate hospitals in 39 states and Puerto Rico, with concentrations in Florida and Texas.'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

10 dimensions · all in-band

GatesA.R:R 1.0 < 1.5@spotMomentum 4.5<5.5 (soft — BUY_NOW allowed but watch)Momentum 4.5>=4.5Insider activity: OKNo SEC red flagsNEWS BOOST EARNINGS 0.80EARNINGS PROXIMITY NO DATESEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARRange BoundSuitability: Moderate
RSI
49 · Neutral
↓ 20D MA↓ 50D MA↑ 200D MAGOLDEN CROSSSupport $118.39Resistance $129.96

Price Targets

$115
$120
$129
A.Upside+5.6%
A.R:R1.0:1

Position Sizing

ConvictionMedium conviction
Suggested %0.5%
Max %1%
RegimeRisk-Off

Risk Alerts

! News modifier +2: HOLD_IF_HOLDING → STRONG_BUY_WAIT
! asymmetry at 1.0 (below the engine's 1.5 threshold)@spot

Earnings

B
B
B
B
4/4 beats
Next Earnings2026-10-28 (Date unconfirmed)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is EHC stock a buy right now?

Wait for pullback to $120.07. At $122.09 the A.R:R is 1.0:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $120.07 (support + ATR (held)) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risk: Thin upside margin: 5.6%. Chart setup: RSI 49 mid-range, Bollinger mid-band. Maintain position. Not compelling to add more. | News modifier +2 (HOLD_IF_HOLDING → STRONG_BUY_WAIT) Target $128.91 (+5.6%), stop $114.84 (−6.3%), A.R:R 1.0:1. Score 5.8/10, moderate confidence.

What is the EHC stock price target?

Take-profit target: $128.91 (+5.6% upside). Target $128.91 (+5.6%), stop $114.84 (−6.3%), A.R:R 1.0:1. Stop-loss: $114.84.

What are the risks of investing in EHC?

Thin upside margin: 5.6%.

Is EHC overvalued or undervalued?

Encompass Health Corporation trades at a P/E of 20.4 (forward 18.3). TrendMatrix value score: 7.2/10. Verdict: Buy (Wait for Entry).

What do analysts say about EHC?

18 analysts cover EHC with a consensus score of 4.3/5. Average price target: $148.

What does Encompass Health Corporation do?Encompass Health Corporation is the nation's largest owner and operator of inpatient rehabilitation hospitals,...

Encompass Health Corporation is the nation's largest owner and operator of inpatient rehabilitation hospitals, operating 173 facilities across 39 states and Puerto Rico, with concentrations in Florida and Texas. The company generated $5.9 billion in net operating revenues in 2025, earning revenue primarily from Medicare, Medicare Advantage, Medicaid, and commercial payors, with 92% of patients admitted from acute-care hospitals following physician referrals.

Related stocks: ASTH (Astrana Health Inc.) · AVAH (Aveanna Healthcare Holdings Inc) · CHE (Chemed Corp) · THC (Tenet Healthcare Corporation) · ADUS (Addus HomeCare Corporation)
Home › Stocks › EHC

Latest news

Latest News

Dars.gov.et92d ago
TradingKey92d ago
Yahoo Finance183d agoEarnings
StockStory13h agoEarnings
Marketscreener.com14h agoEarnings
Yahoo Finance15h agoEarnings
GuruFocus190d ago
Yahoo Finance8d ago
StockStory43d agoEarnings
StockStory78d agoEarnings
TipRanks50d ago
Simplywall.st50d ago
Simply Wall Street22d ago
Yahoo Finance176d ago
MarketBeat85d agoEarnings
StockStory85d ago
Quiver Quantitative85d agoEarnings
Simplywall.st85d ago